Other tumours: Biomarkers panel for Solid Tumors by NGS
Speciality(ies) / Other Speciality(ies)
Oncology
Pathology
Methodology
NGS
SNS Code
34900
OMIM
–
Gene Number
–
Test / Mutation List
Mutations (Hotspots – 35 genes): AKT1; ALK; AR; BRAF; CDK4; CTNNB1; DDR2; EGFR; ERBB2 (HER2); ERBB3 (HER3); ERBB4 (HER4); ESR1; FGFR2; FGFR3; GNA11; GNAQ; HRAS; IDH1; IDH2; JAK1; JAK2; JAK3; KIT; KRAS; MAP2K1 (MEK1); MAP2K2 (MEK2); MET; MTOR; NRAS; PDGFRA; PIK3CA; RAF1; RET; ROS1; SMO
Fusion drivers (23 genes): ABL1; AKT3; ALK; AXL; BRAF; EGFR; EGFRvIII; ERBB2 (HER2); ERG; ETV1; ETV4; ETV5; FGFR1; FGFR2; FGFR3; MET; NTRK1; NTRK2; NTRK3; PDGFRA; PPARG; RAF1; RET; ROS1
CNVs (19 genes): AKT1; ALK; AR; BRAF; CCND1; CDK4; CDK6; EGFR; ERBB2 (HER2); FGFR1; FGFR2; FGFR3; FGFR4; KIT; KRAS; MET; MYC; MYCN; PDGFRA; PIK3CA
(To proceed with CNVs analysis it is necessary the percentage of neoplastic cells in the sample)
TAT
15 to 20 working days
Sample Type
Formalin fix and paraffin embed tumour tissue; stable at room temperature (RT)
(6×20μm sections or tissue block or cellblock, with a fresh H&E slide)
or
Cytological sample in collection medium; stable for 4-6 weeks